Anti-GPC3 CAR T for Treating Patients With Advanced HCC

Summary

The purpose of this study is to determine whether autologous T cells bearing chimeric antigen receptor that can specifically recognize glypican-3 (GPC3) is safe and effective for patients with relapsed or refractory hepatocellular carcinoma (HCC).

Timeline

Start

2015-03

Primary completion

2016-06

Completion

2018-11

Publications

• Shi Y, Shi D, Chi J, Cui D, Tang X, Lin Y, Wang S, Li Z, Jin H, Zhai B. Combined local therapy and CAR-GPC3 T-cell therapy in advanced hepatocellular carcinoma: a proof-of-concept treatment strategy. Cancer Commun (Lond). 2023 Sep;43(9):1064-1068. doi: 10.1002/cac2.12472. Epub 2023 Jul 21. No abstract available.

Drugs

Indications